This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Viatris fined by UK CMA for compliance fault over Theramex-Viatris deal

( November 22, 2024, 10:58 GMT | Official Statement) -- MLex Summary: Viatris has been fined 1.5 million pounds ($1.9 million) by the UK competition regulator for failing to comply with compulsory restrictions imposed during the watchdog's review of its deal with Theramex. In August, Theramex gained UK approval to acquire the European rights to Viatris’ Femoston and Duphaston menopause treatments. The deal excludes the UK rights after an initial probe by the Competition and Markets Authority raised concerns that the deal could reduce choice and lead to higher prices for hormone replacement therapy.Statement follows....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login